Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy

Department of Internal Medicine, University of Turin, Italy. janssen@inw3.azr.nl

OBJECTIVE: Ghrelin stimulates growth hormone (GH) secretion both in vivo and in vitro. Ghrelin is mainly produced in and released from the stomach but it is probably also produced in the hypothalamic arcuate nucleus. Whether pituitary GH release is under the control of ghrelin from the stomach and/or from the arcuate nucleus is not known. Moreover, no data on the feedback of GH on systemic ghrelin concentrations are available. It has recently been suggested that ghrelin may induce obesity. DESIGN: In this study, we addressed the following two questions: a) are circulating ghrelin levels increased in human GH deficiency (GHD), and b) does GH treatment modify ghrelin levels in human GHD? METHODS: The study group consisted of 23 patients with GHD. Eighteen had developed adult-onset GHD and five had developed GHD in their childhood (childhood-onset GHD). Ghrelin was measured with a commercially available radioimmunoassay. All measurements were performed twice, first at baseline, before the start of GH replacement therapy, and then again after one year of therapy. GH doses were adjusted every 3 months, targeting serum total IGF-I levels within the normal gender- and age-related reference values for the healthy population. Maintenance doses were continued once the target serum total IGF-I levels were reached. RESULTS: The sum of skinfolds and body water increased significantly, body fat mass and percentage body fat decreased significantly and body mass index and waist-hip ratio were not significantly changed by one year of GH replacement therapy.Before the start of GH replacement therapy, mean value and range for fasting ghrelin in the studied GHD subjects tended to be lower in comparison with healthy subjects in the control group although the difference did not reach significance (GHD ghrelin mean 67.8 pmol/l, range 37.6-116.3 pmol/l; control mean 83.8 pmol/l, range 35.4-132 pmol/l; P=0.11).One year of GH replacement therapy did not modify circulating ghrelin levels (ghrelin before GH therapy: 67.8 pmol/l, range 37.6-116.3 pmol/l; after GH therapy: 65.3 pmol/l, range 35.8-112.6; P=0.56). CONCLUSIONS: We did not observe elevated ghrelin levels in adult GHD subjects and GH replacement therapy did not modify circulating ghrelin levels, despite significant decreases in body fat mass and percentage body fat. It is conceivable that the lack of ghrelin modifications after long-term GH therapy was due to the reduction of adiposity and insulin on one hand, and increased GH secretion on the other. However, it is still possible that systemic ghrelin is involved in the development of obesity, both in normal and GHD subjects.

This article has been cited by other articles:

				B. P. Hauffa, K. Haase, I. M. Range, N. Unger, K. Mann, and S. Petersenn The Effect of Growth Hormone on the Response of Total and Acylated Ghrelin to a Standardized Oral Glucose Load and Insulin Resistance in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 834 - 840. [Abstract] [Full Text] [PDF]

				P. Koutkia, S. Schurgin, J. Berry, J. Breu, B. S. H. Lee, A. Klibanski, and S. Grinspoon Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E814 - E822. [Abstract] [Full Text] [PDF]

				C. Daousi, I. A. MacFarlane, P. J. English, J. P. H. Wilding, M. Patterson, T. M. Dovey, J. C. G. Halford, M. A. Ghatei, and J. H. Pinkney Is There a Role for Ghrelin and Peptide-YY in the Pathogenesis of Obesity in Adults with Acquired Structural Hypothalamic Damage? J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5025 - 5030. [Abstract] [Full Text] [PDF]

				L. Ghizzoni, G. Mastorakos, A. Vottero, M. Ziveri, I. Ilias, and S. Bernasconi Spontaneous Growth Hormone (GH) Secretion Is Not Directly Affected by Ghrelin in Either Short Normal Prepubertal Children or Children with GH Neurosecretory Dysfunction J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5488 - 5495. [Abstract] [Full Text] [PDF]

				G. Rindi, A. Torsello, V. Locatelli, and E. Solcia Ghrelin Expression and Actions: A Novel Peptide for an Old Cell Type of the Diffuse Endocrine System Experimental Biology and Medicine, November 1, 2004; 229(10): 1007 - 1016. [Abstract] [Full Text] [PDF]

				C. Gauna, F. M. Meyler, J. A. M. J. L. Janssen, P. J. D. Delhanty, T. Abribat, P. van Koetsveld, L. J. Hofland, F. Broglio, E. Ghigo, and A. J. van der Lely Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5035 - 5042. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, M. L. Johnson, and S. K. Grinspoon Nocturnal ghrelin pulsatility and response to growth hormone secretagogues in healthy men Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E506 - E512. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				A. P. Goldstone, E. L. Thomas, A. E. Brynes, G. Castroman, R. Edwards, M. A. Ghatei, G. Frost, A. J. Holland, A. B. Grossman, M. Korbonits, et al. Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1718 - 1726. [Abstract] [Full Text] [PDF]

				A. INUI, A. ASAKAWA, C. Y. BOWERS, G. MANTOVANI, A. LAVIANO, M. M. MEGUID, and M. FUJIMIYA Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ FASEB J, March 1, 2004; 18(3): 439 - 456. [Abstract] [Full Text] [PDF]

				J. L. Chan, J. Bullen, J. H. Lee, N. Yiannakouris, and C. S. Mantzoros Ghrelin Levels Are Not Regulated by Recombinant Leptin Administration and/or Three Days of Fasting in Healthy Subjects J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 335 - 343. [Abstract] [Full Text] [PDF]

				Y. Hataya, T. Akamizu, H. Hosoda, N. Kanamoto, K. Moriyama, K. Kangawa, K. Takaya, and K. Nakao Alterations of Plasma Ghrelin Levels in Rats with Lipopolysaccharide-Induced Wasting Syndrome and Effects of Ghrelin Treatment on the Syndrome Endocrinology, December 1, 2003; 144(12): 5365 - 5371. [Abstract] [Full Text] [PDF]

				B. E. Engstrom, P. Burman, C. Holdstock, and F. A. Karlsson Effects of Growth Hormone (GH) on Ghrelin, Leptin, and Adiponectin in GH-Deficient Patients J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5193 - 5198. [Abstract] [Full Text] [PDF]

				F. Tassone, F. Broglio, S. Destefanis, S. Rovere, A. Benso, C. Gottero, F. Prodam, R. Rossetto, C. Gauna, A. J. van der Lely, et al. Neuroendocrine and Metabolic Effects of Acute Ghrelin Administration in Human Obesity J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5478 - 5483. [Abstract] [Full Text] [PDF]

				A. M. Haqq, D. D. Stadler, R. G. Rosenfeld, K. L. Pratt, D. S. Weigle, R. S. Frayo, S. H. LaFranchi, D. E. Cummings, and J. Q. Purnell Circulating Ghrelin Levels Are Suppressed by Meals and Octreotide Therapy in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3573 - 3576. [Abstract] [Full Text] [PDF]

				J. C. Bunt, A. D. Salbe, M. H. Tschop, A. DelParigi, P. Daychild, and P. A. Tataranni Cross-Sectional and Prospective Relationships of Fasting Plasma Ghrelin Concentrations with Anthropometric Measures in Pima Indian Children J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3756 - 3761. [Abstract] [Full Text] [PDF]

				C. Holdstock, B. E. Engstrom, M. Ohrvall, L. Lind, M. Sundbom, and F. A. Karlsson Ghrelin and Adipose Tissue Regulatory Peptides: Effect of Gastric Bypass Surgery in Obese Humans J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3177 - 3183. [Abstract] [Full Text] [PDF]

				P. U. Freda, C. M. Reyes, I. M. Conwell, R. E. Sundeen, and S. L. Wardlaw Serum Ghrelin Levels in Acromegaly: Effects of Surgical and Long-Acting Octreotide Therapy J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2037 - 2044. [Abstract] [Full Text] [PDF]

				A. L. Barkan, E. V. Dimaraki, S. K. Jessup, K. V. Symons, M. Ermolenko, and C. A. Jaffe Ghrelin Secretion in Humans Is Sexually Dimorphic, Suppressed by Somatostatin, and Not Affected by the Ambient Growth Hormone Levels J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2180 - 2184. [Abstract] [Full Text] [PDF]

				A. M. Haqq, D. D. Stadler, R. H. Jackson, R. G. Rosenfeld, J. Q. Purnell, and S. H. LaFranchi Effects of Growth Hormone on Pulmonary Function, Sleep Quality, Behavior, Cognition, Growth Velocity, Body Composition, and Resting Energy Expenditure in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2206 - 2212. [Abstract] [Full Text] [PDF]

				A. L. D. Riis, T. K. Hansen, N. Moller, J. Weeke, and J. O. L. Jorgensen Hyperthyroidism Is Associated with Suppressed Circulating Ghrelin Levels J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 853 - 857. [Abstract] [Full Text] [PDF]

				A. M. Haqq, I. S. Farooqi, S. O'Rahilly, D. D. Stadler, R. G. Rosenfeld, K. L. Pratt, S. H. LaFranchi, and J. Q. Purnell Serum Ghrelin Levels Are Inversely Correlated with Body Mass Index, Age, and Insulin Concentrations in Normal Children and Are Markedly Increased in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 174 - 178. [Abstract] [Full Text] [PDF]

				A. DelParigi, M. Tschop, M. L. Heiman, A. D. Salbe, B. Vozarova, S. M. Sell, J. C. Bunt, and P. A. Tataranni High Circulating Ghrelin: A Potential Cause for Hyperphagia and Obesity in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5461 - 5464. [Abstract] [Full Text] [PDF]